U.S. Missile Stockpiles Dwindle. And, FDA Weighs Approval of Flu Shots with mRNA Tech

FDA approves 1st mRNA flu shot, from Moderna

A pharmacist administers a third dose of the Moderna Covid-19 vaccine to a customer at a pharmacy in Livonia, Michigan, U.S., on Tuesday, Aug. 17, 2021.

FDA approves Moderna’s mRNA flu vaccine, the first to use the technology

Moderna's mFlusiva to be first mRNA-based flu shot on the market. Approval caps remarkable turn of fortune for technology long targeted by vaccine skeptics.

U.S. missile stockpiles dwindle. And, FDA weighs approval of flu shots with mRNA tech

The U.S. Army's missile stockpile is dwindling and could take years to replenish. And, the Food and Drug Administration is deciding whether to approve a flu vaccine with mRNA technology.

FDA is poised to decide whether to approve the first mRNA flu vaccine

The FDA will soon decide whether to approve the first flu vaccine that uses the same mRNA technology as COVID-19 shots. Health Secretary Robert F. Kennedy Jr. has long questioned mRNA vaccines.

The FDA’s Decision Day on Moderna’s mRNA Flu Shot Is Here — What Investors Need to Know

Wednesday, August 5, 2026 is a landmark moment for Moderna — and potentially for vaccine history. The FDA’s PDUFA target action date for mFlusiva (mRNA-1010), Moderna’s seasonal influenza vaccine candidate, falls today, meaning the agency is expected to issue a final approval decision by market close. If approved, mFlusiva will become the first mRNA-based seasonal flu vaccine ever licensed in the United States, extending Moderna’s platform well …